Compositions of myeloid-cell-suppressive chemokines
AssigneeIndiana University Foundation
InventorsHal E. Broxmeyer, Scott Cooper, Charles Mantel, Li Lu
Life of this patent
Estimating the term…
Abstract
Described are preferred processes for suppressing proliferation of or for myeloprotecting myeloid cells in mammals. The processes involve the use of chemokines of the group Macrophage Inflammatory Protein-2.alpha. (MIP-2.alpha.), Platelet Factor 4 (PF4), Interleukin-8 (IL-8) and Macrophage Chemotactic and Activating Factor (MCAF), or involve the use of these chemokines or Macrophage Inflammatory Protein-1.alpha. (MIP-1.alpha.) in synergistic combinations or while they are substantially completely in monomeric form (i.e. substantially free from their polymerized or aggregated forms).
Claims22
A composition capable of suppressing proliferation of mammalian myeloid cells, comprising:
- a buffered solution of one or more chemokines from the MIP-1.alpha. or MIP-1.beta. family which is active to suppress proliferation of mammalian myeloid cells, wherein said one more chemokines are present at a concentration sufficient to maintain said one or more chemokines essentially in monomeric form.
A composition comprising:
- a combination of two or more chemokines which suppress proliferation of mammalian myeloid cells, said combination exhibiting synergism in the suppression of proliferation of mammalian myeloid cells, and wherein said combination comprises at least two chemokines selected from the group consisting of MIP-1.alpha., MIP-2.alpha., PF4, IL-8 and MCAF.
A composition comprising:
- a buffered solution containing a monomeric chemokine selected from chemokines belonging to the MIP-1.alpha. and MIP-1.beta. families which is active to suppress proliferation of mammalian myeloid cells, said composition being substantially free from aggregates of said chemokine and further being stable against aggregation of said chemokine for three weeks when stored at a temperature of 4.degree. C., and wherein said chemokine is present at a concentration sufficient to maintain said chemokine essentially in monomeric form.
Dependencies are inferred from the claim text.